Is protease inhibitor a choice for the treatment of pre- or mild disseminated intravascular coagulation?

Critical Care Medicine

Volumn 28, Issue 5, 2000, Pages 1419-1422

  Nishiyama, Tomoki ^a,c   Matsukawa, Takashi ^b   Hanaoka, Kazuo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

^c NONE   (Japan)

Author keywords

Antithrombin III; D dimer; Disseminated intravascular coagulation; Fibrin degradation product; Fibrin monomer; Fibrinogen; Plasmin plasmin inhibitor complex; Platelet; Protease inhibitor; Prothrombin time; Thrombin antithrombin III complex

Indexed keywords

ANTIPLASMIN; ANTITHROMBIN III; D DIMER; FIBRIN DEGRADATION PRODUCT; FIBRIN MONOMER; FIBRINOGEN; GABEXATE MESILATE; PLASMIN; PROTEINASE INHIBITOR; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG HALF LIFE; FEMALE; FIBRINOLYSIS; HUMAN; INTENSIVE CARE UNIT; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034112721     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200005000-00027     Document Type: Article

References (17)

1. 1. Baker WF: Clinical aspects of disseminated intravascular coagulation: A clinician's point of view. Semin Thromb Hemost 1989; 15: 1-57
2. 2. Bick RL: Disseminated intravascular coagulation and related syndromes: A clinical review. Semin Thromb Hemost 1988; 14: 299-338
3. 3. Rosenberg RD: Biologic actions of heparin. Semin Hematol 1977; 14:427-440
4. 4. Taenaka N, Shimada Y, Hirata T, et al: Gabexate mesilate (FOY) therapy of disseminated intravascular coagulation due to sepsis. Crit Care Med 1983; 11:735-738
5. 5. Ohno H, Kosaki G, Kambayashi J: FOY: [Ethyl p-(6-guanidino hexanoyloxy) benzoate] methanesulfonate as a serine protease inhibitor. I. Inhibition of thrombin and factor Xa in vitro. Thromb Res 1980; 19:579-588
6. 6. Kazama M: Diagnosis and treatment of DIC: Present status. Med Postgrad 1992; 30:64-72
7. 7. Shifman M, Pizzo S: The in vivo metabolism of antithrombin III and antithrombin III complexes. J Biol Chem 1982; 257: 3243-3248
8. 8. Pelzer H, Schwarz A, Heimburger N: Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988; 59:101-106
9. 9. Wada H, Wakita Y, Nakase T, et al: Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation. Am J Hematol 1996; 51:255-260
10. 10. Wada H, Wakita Y, Nakase T, et al: Diagnosis of pre-disseminated intravascular coagulation stage with hemostatic molecular markers. Pol J Pharmacol 1996; 48:225-228
11. 11. Elms MJ, Bunce IH, Bundesen PG, et al: Measurement of crosslinked fibrin degradation products: An immunoassay using monoclonal antibodies. Thromb Haemost 1983; 50:591-594
12. 12. Owings JT, Bagley M, Gosselin R, et al: Effect of critical injury on plasma antithrombin activity: Low antithrombin levels are associated with thromboembolic complications. J Trauma 1996; 41:396-406
13. 13. Fourrier F, Chopin C, Goudemand J, et al: Septic shock, multiple organ failure, and disseminated intravascular coagulation: Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992; 101: 816-823
14. 14. Bredbacka S, Blombäck M, Wiman B, et al: Laboratory methods for detecting disseminated intravascular coagulation (DIC): New aspects. Acta Anaesthesiol Scand 1993; 37: 125-130
15. 1 esterase. Biochim Biophys Acta 1977; 484:417-422
16. 16. Ohno H, Kambayashi J, Chang SW, et al: FOY: [Ethyl p-(6-guanidino hexanoyloxy) benzoate] methanesulfonate as a serine protease inhibitor. II. In vitro effect on coagulofibrinolytic system in comparison with heparin or aprotinin. Thromb Res 1981; 24: 445-452
17. 17. Gabexate mesilate. In: Drugs in Japan. Tokyo, Japan Pharmaceutical Information Center. 1992, pp 272-273